Veraxa Biotech Holding AG
Veraxa Biotech Holding AG
- Market cap
- $145.65M
Your view on VRXA
Overview
What the company does, where it operates, and who runs it.
About Veraxa Biotech Holding AG
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Christoph Antz
- Headquarters
- Im Neuenheimer Feld 584, Heidelberg, ZH, DE
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Christoph Antz
- Headquarters
- Im Neuenheimer Feld 584, Heidelberg, ZH, DE
Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed via a merger with Voyager Acquisition Corp., focusing on developing next-generation cancer therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers. [64, 65]
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Veraxa Biotech Holding AG. Starting points for Veraxa Biotech Holding AG: EPS -$0.58, beta 0.26 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Veraxa Biotech Holding AG. Trailing twelve-month EPS for Veraxa Biotech Holding AG stands at -$0.58. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Veraxa Biotech Holding AG. Veraxa Biotech Holding AG has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| NTI.AXNeurotech International Limited | Healthcare | ASX | — | ||
| NTIINeurobiological Technologies, Inc. | Healthcare | OTC | $2,702 | ||
| NTLAIntellia Therapeutics, Inc. | Healthcare | NASDAQ | $1.4B | ||
| NTRBNutriband Inc. | Healthcare | NASDAQ | $58.6M | ||
| NTRBWNutriband Inc. | Healthcare | NASDAQ | $76.8M | ||
| NTRRNeutra Corp. | Healthcare | OTC | $291,790 | ||
| NURPFNeuren Pharmaceuticals Limited | Healthcare | OTC | $1.1B | ||
| NUVBNuvation Bio Inc. | Healthcare | NYSE | $1.3B | ||
| NUZ.AXNeurizon Therapeutics Limited | Healthcare | ASX | — | ||
| NVAXNovavax, Inc. | Healthcare | NASDAQ | $1.3B | ||
| NVCTNuvectis Pharma, Inc. | Healthcare | NASDAQ | $697.8M | ||
| NWBONorthwest Biotherapeutics, Inc. | Healthcare | OTC | $359.4M | ||
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Veraxa Biotech Holding AG executives and directors. Shares of Veraxa Biotech Holding AG have traded between $1.70 and $27.36 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Veraxa Biotech Holding AG. Coverage tracks Veraxa Biotech Holding AG within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Veraxa Biotech Holding AG.